Bausch and Health

inc: Bausch Health Companies Inc. raised its guidance as it reported a first-quarter loss of US 52 million, according to The Toronto Star. The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., Wednesday, February 20, 2019. The stock closed up 2.88, or 9.16 per cent, at 34.31. Ryan Remiorz / THE CANADIAN PRESS Bausch & Lomb, a segment that generates more than half of the drug company's revenue, saw revenue rise eight per cent to US 1.12 billion, after adjusting for foreign exchange, divestitures and discontinuations, according to the company. The Quebec-based company, formerly called Valeant Inc., increased research and development investment by about 30 per cent, part of Papa's shift away from an aggressive acquisition strategy and focus on returning to the black. Clearly the majority of the growth in our Bausch & Lomb franchise is driven by the volume, chief executive Joseph Papa said. (news.financializer.com). As reported in the news.